PharmaEngine, Inc. (TPEX:4162)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
65.80
+1.40 (2.17%)
Sep 18, 2025, 1:30 PM CST
2.17%
Market Cap9.25B
Revenue (ttm)2.48B
Net Income (ttm)1.63B
Shares Out143.68M
EPS (ttm)11.33
PE Ratio5.69
Forward PE26.95
Dividend6.00 (9.32%)
Ex-Dividend DateAug 13, 2025
Volume402,885
Average Volume594,919
Open65.20
Previous Close64.40
Day's Range65.10 - 66.00
52-Week Range63.90 - 123.00
Beta0.26
RSI33.85
Earnings DateNov 10, 2025

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 44
Stock Exchange Taipei Exchange
Ticker Symbol 4162
Full Company Profile

Financial Performance

In 2024, PharmaEngine's revenue was 2.52 billion, an increase of 228.70% compared to the previous year's 767.67 million. Earnings were 1.75 billion, an increase of 537.55%.

Financial Statements

News

There is no news available yet.